Smith Group Asset Management LLC Grows Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX

Posted by Stanley Muller on Jul 29th, 2026

Smith Group Asset Management LLC boosted its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 7.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 55,746 shares of the pharmaceutical company’s stock after purchasing an additional 3,695 shares during the period. Smith Group Asset Management LLC’s holdings in Vertex Pharmaceuticals were worth $24,893,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in VRTX. Allworth Financial LP raised its stake in shares of Vertex Pharmaceuticals by 414.1% in the fourth quarter. Allworth Financial LP now owns 14,036 shares of the pharmaceutical company’s stock worth $6,363,000 after buying an additional 11,306 shares during the period. Calamos Advisors LLC grew its stake in shares of Vertex Pharmaceuticals by 77.1% during the 1st quarter. Calamos Advisors LLC now owns 77,886 shares of the pharmaceutical company’s stock valued at $34,779,000 after acquiring an additional 33,917 shares during the period. Sandro Wealth Management LLC bought a new position in shares of Vertex Pharmaceuticals during the 4th quarter valued at approximately $1,436,000. Fideuram Intesa Sanpaolo Private Banking S.P.A. increased its holdings in Vertex Pharmaceuticals by 11.9% in the 1st quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. now owns 34,991 shares of the pharmaceutical company’s stock worth $15,625,000 after acquiring an additional 3,710 shares in the last quarter. Finally, LBP AM SA increased its holdings in Vertex Pharmaceuticals by 51.8% in the 4th quarter. LBP AM SA now owns 67,197 shares of the pharmaceutical company’s stock worth $30,464,000 after acquiring an additional 22,918 shares in the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Insider Activity

In other Vertex Pharmaceuticals news, EVP Joy Liu sold 1,104 shares of the stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $425.02, for a total transaction of $469,222.08. Following the completion of the transaction, the executive vice president owned 20,729 shares of the company’s stock, valued at $8,810,239.58. This represents a 5.06% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Duncan Mckechnie sold 1,541 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $519.00, for a total value of $799,779.00. Following the transaction, the executive vice president owned 11,001 shares of the company’s stock, valued at approximately $5,709,519. The trade was a 12.29% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 18,874 shares of company stock valued at $8,707,966 in the last quarter. Company insiders own 0.20% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on VRTX. Royal Bank Of Canada raised their target price on shares of Vertex Pharmaceuticals from $543.00 to $570.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. Barclays upped their price target on shares of Vertex Pharmaceuticals from $607.00 to $615.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. UBS Group increased their price objective on shares of Vertex Pharmaceuticals from $545.00 to $585.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. Canaccord Genuity Group decreased their price objective on shares of Vertex Pharmaceuticals from $437.00 to $436.00 and set a “hold” rating on the stock in a research report on Tuesday, May 5th. Finally, Morgan Stanley upped their target price on shares of Vertex Pharmaceuticals from $612.00 to $616.00 and gave the stock an “overweight” rating in a report on Tuesday, May 5th. Twenty-two research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $559.61.

Get Our Latest Analysis on Vertex Pharmaceuticals

Vertex Pharmaceuticals Trading Up 2.4%

NASDAQ VRTX opened at $490.39 on Wednesday. Vertex Pharmaceuticals Incorporated has a 12 month low of $362.50 and a 12 month high of $533.67. The stock has a market cap of $124.46 billion, a PE ratio of 29.09, a P/E/G ratio of 2.16 and a beta of 0.29. The stock’s 50 day moving average is $467.74 and its 200 day moving average is $459.99.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last announced its quarterly earnings data on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.24 by $0.23. The business had revenue of $2.99 billion during the quarter, compared to analyst estimates of $2.99 billion. Vertex Pharmaceuticals had a net margin of 35.51% and a return on equity of 23.86%. The company’s revenue was up 8.3% on a year-over-year basis. During the same period last year, the firm posted $4.06 EPS. On average, analysts forecast that Vertex Pharmaceuticals Incorporated will post 17.01 EPS for the current fiscal year.

Vertex Pharmaceuticals Company Profile

(Free Report)

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.